Digital Health and HealthTech IPO Performances in the Last 12 Months: Tempus AI, Waystar, Caris Life Sciences, Hinge Health, Omada Health, Kestra Medical

Why It Matters

Health Tech 2.0 demonstrates that sustainable unit economics and AI integration can unlock multi‑billion‑dollar valuations, reshaping capital allocation in the broader tech sector. The split performance signals where future funding and M&A activity will concentrate within digital health.

Key Takeaways

• Health Tech 2.0 cohort added $36.6 B market cap in 2025
• Hinge Health posted 72% YoY growth and Rule‑of‑40 score 98
• Tempus AI rose 31% post‑IPO, trading at 9.3× EV/Revenue
• Omada Health shares fell 23% despite 42% revenue increase
• Investors favor AI‑driven, high‑margin firms over traditional service models

Pulse Analysis

The emergence of Health Tech 2.0 reflects a fundamental re‑rating of digital‑health firms. Analysts now apply cloud‑software benchmarks—Rule of 40, ARR per full‑time employee—to gauge durability, and the cohort’s $36.6 billion market‑cap creation in 2025 underscores the premium placed on AI‑enabled data assets and clear paths to profitability. This shift has narrowed the valuation gap with traditional SaaS, yet a 10‑20% "trust‑gap" discount remains as investors demand proof that AI can sustain operating leverage in clinical environments.

Performance data reveal a clear bifurcation. Hinge Health’s 71.9% share surge, 72% revenue growth and a Rule‑of‑40 score of 98 illustrate how a non‑commodity hardware component and AI‑driven therapy platform can generate high‑margin, recurring revenue. Tempus AI, despite a negative free‑cash‑flow margin, leverages a massive genomic data moat, justifying a 9.3× EV/revenue multiple. Conversely, Omada Health and Caris Life Sciences, though posting double‑digit revenue growth, have seen share price erosion as markets question the scalability of their service‑heavy models. Waystar’s flat performance highlights integration risk even with solid EBITDA margins.

Looking ahead, AI is poised to become a decisive valuation multiplier. By late 2026, hospitals and payers will likely require quantifiable ROI on AI applications, pressuring firms that cannot demonstrate cost‑savings or outcome improvements. The macro backdrop—post‑Warsh shock capital rotation, deregulation under the MAHA agenda, and favorable UK‑US trade terms—creates fertile ground for M&A, especially in oncology and musculoskeletal care. Companies that cement infrastructure‑grade metrics and expand globally stand to capture the next wave of investment, while laggards risk further compression as the market tightens around proven, AI‑native business models.